Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia.
This article reviews the proposed pathophysiological mechanism underlying the phenomenon of dopamine agonist valvulopathy, the characteristic echocardiographic changes seen, summarises the published literature on the incidence of valvulopathy with low dose cabergoline and examines the previous and current evidence-based screening guidelines.
PMID: 32178837 [PubMed - as supplied by publisher]
Source: Annales d'Endocrinologie - Category: Endocrinology Authors: Stiles CE, Steeds RP, Drake WM Tags: Ann Endocrinol (Paris) Source Type: research
More News: Endocrinology